Evidence map›Paper›PMID 38767042›Full record

ArticleClinical cardiology2024

Efficacy and safety of semaglutide in patients with heart failure with preserved ejection fraction and obesity.

Ayesha Rehman, Shahab Saidullah, Muhammad Asad, Umer R Gondal, Amna Ashraf, Muhammad F Khan, Waheed Akhtar, Amin Mehmoodi, Jahanzeb Malik

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ayesha RehmanDepartment of Medicine, Quaid e Azam Medical College, Bahawalpur, Pakistan.
Shahab SaidullahDepartment of Cardiology, Pakistan Institute of Medical Sciences, Islamabad, Pakistan.
Muhammad AsadDepartment of Cardiology, Benazir Bhutto Hospital, Rawalpindi, Pakistan.
Umer R GondalDepartment of Medicine, Reading Hospital, West Reading, PA, USA.
Amna AshrafDepartment of Medicine, Military Hospital, Rawalpindi, Pakistan.
Muhammad F KhanDepartment of Medicine, Ayub Teaching Hospital, Abbottabad, Pakistan.
Waheed AkhtarDepartment of Cardiology, Abbas Institute of Medical Sciences, Muzaffrabad, Pakistan.
Amin MehmoodiDepartment of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan.ORCID http://orcid.org/0000-0003-4968-3909
Jahanzeb MalikDepartment of Cardiovascular Medicine, Cardiovascular Analytics Group, Islamabad, Pakistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSemaglutide, a once-weekly glucagon-like peptide-1 receptor agonist, has shown promise in weight management and cardiovascular outcomes in other populations. This study aimed to evaluate the efficacy of semaglutide in heart failure with preserved ejection fraction (HFpEF) patients with obesity.

methodsA retrospective study analyzed 318 patients with HFpEF, of which 104 received semaglutide and 214 received placebo. Primary endpoints included evaluating changes in exercise capacity and weight management.

resultsSemaglutide treatment led to significant improvements in the primary endpoints. Patients in the semaglutide group demonstrated substantial enhancements in exercise capacity, as measured by the 6-min walk distance, compared to the placebo group (mean difference 15.1 meters, 95% CI 5.8 to 24.4, p = 0.002). Additionally, semaglutide resulted in substantial weight loss compared to placebo (mean difference -2.9%, 95% CI -4.1--1.7, p = 0.001). Several secondary endpoints, including reductions in C-reactive protein levels and improvements in other clinical parameters, further supported the efficacy of semaglutide. Adverse events were generally well-tolerated, with no unexpected safety concerns.

conclusionSemaglutide demonstrated significant clinical benefits in HFpEF patients with obesity, as evidenced by improved symptoms, physical function, and weight reduction.

Indexed as

Glucagon-Like PeptidesHeart FailureObesityStroke VolumeAgedExercise ToleranceFemaleGlucagon-Like Peptide-1 Receptor AgonistsHumansMaleMiddle AgedRecovery of FunctionRetrospective StudiesSemaglutideTime FactorsTreatment OutcomeGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesSemaglutideexercise capacityheart failure with preserved ejection fractionobesitysemaglutideweight management

Identifiers

PMID38767042
PMCPMC11103635

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.